Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MGAM | O43451 | 4/20 | 0.33 |
| ▸ | GAA | P10253 | 4/20 | 0.33 |
| ▸ | SI | P14410 | 4/20 | 0.33 |
| ▸ | MGAM2 | Q2M2H8 | 4/20 | 0.33 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.33 |
| ▸ | NR3C1 | P04150 | 3/20 | 0.32 |
| ▸ | PGR | P06401 | 3/20 | 0.32 |
| ▸ | NR3C2 | P08235 | 3/20 | 0.32 |
| ▸ | AR | P10275 | 3/20 | 0.32 |
| ▸ | KDR | P35968 | 1/20 | 0.32 |
| ▸ | GUSB | P08236 | 2/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | CYP3A5 | P20815 | 1/20 | 0.32 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7978938 | 0.92 | KDR (0.35) | NR3C1PGRNR3C2ARKDR | |
| SCHEMBL1350089 | 0.92 | KDR (0.36) | NR3C1PGRNR3C2ARKDR | |
| SCHEMBL1349674 | 0.92 | NR3C1 (0.34) | MGAMGAASIMGAM2NR3C1 | |
| SCHEMBL1350016 | 0.91 | MGAM (0.34) | MGAMGAASIMGAM2CYP19A1 | |
| SCHEMBL1349055 | 0.90 | CYP19A1 (0.37) | MGAMGAASIMGAM2CYP19A1 | |
| SCHEMBL1349821 | 0.89 | CYP19A1 (0.33) | MGAMGAASIMGAM2CYP19A1 | |
| SCHEMBL1350220 | 0.89 | PSEN1 (0.33) | MGAMGAASIMGAM2GUSB | |
| SCHEMBL1348489 | 0.89 | KDR (0.33) | NR3C1PGRNR3C2ARKDR | |
| SCHEMBL1351060 | 0.87 | NR3C1 (0.39) | GAANR3C1PGRNR3C2AR | |
| SCHEMBL1348451 | 0.85 | NR3C1 (0.33) | MGAMGAASIMGAM2NR3C1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8063234-B2 | Substituted 7-sulfanylmethyl-, 7-sulfinylmethyl- and 7-sulfonylmethylindoles and the use thereof | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2011-11-22 | — | — | US | disclosed |
| US-8063234-B2 | Substituted 7-sulfanylmethyl-, 7-sulfinylmethyl- and 7-sulfonylmethylindoles and the use thereof | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2011-11-22 | — | — | US | disclosed |
| US-8063234-B2 | Substituted 7-sulfanylmethyl-, 7-sulfinylmethyl- and 7-sulfonylmethylindoles and the use thereof | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2011-11-22 | — | — | US | disclosed |
| US-20110201564-A1 | SUBSTITUTED 7-SULFANYLMETHYL, 7-SULFINYLMETHYL AND 7-SULFONYLMETHYL INDOLES AND USE THEREOF | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2011-08-18 | — | — | US | disclosed |
| US-20110201564-A1 | SUBSTITUTED 7-SULFANYLMETHYL, 7-SULFINYLMETHYL AND 7-SULFONYLMETHYL INDOLES AND USE THEREOF | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2011-08-18 | — | — | US | disclosed |
| US-20110201564-A1 | SUBSTITUTED 7-SULFANYLMETHYL, 7-SULFINYLMETHYL AND 7-SULFONYLMETHYL INDOLES AND USE THEREOF | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2011-08-18 | — | — | US | disclosed |
| US-20100105744-A1 | SUBSTITUTED 7-SULFANYLMETHYL-, 7-SULFINYLMETHYL- AND 7-SULFONYLMETHYLINDOLES AND THE USE THEREOF | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-04-29 | — | — | US | disclosed |
| US-20100105744-A1 | SUBSTITUTED 7-SULFANYLMETHYL-, 7-SULFINYLMETHYL- AND 7-SULFONYLMETHYLINDOLES AND THE USE THEREOF | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-04-29 | — | — | US | disclosed |
| US-20100105744-A1 | SUBSTITUTED 7-SULFANYLMETHYL-, 7-SULFINYLMETHYL- AND 7-SULFONYLMETHYLINDOLES AND THE USE THEREOF | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-04-29 | — | — | US | disclosed |
| WO-2009156072-A1 | SUBSTITUTED 7-SULFANYLMETHYL, 7-SULFINYLMETHYL AND 7-SULFONYLMETHYL INDOLES AND USE THEREOF | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2009-12-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100105744-A1 | SUBSTITUTED 7-SULFANYLMETHYL-, 7-SULFINYLMETHYL- AND 7-SULFONYLMETHYLINDOLES AND THE USE THEREOF | STS, HTR7, PCSK7 | MGAM 457/4885GAA 944/4885SI 106/4885 |
| US-20110201564-A1 | SUBSTITUTED 7-SULFANYLMETHYL, 7-SULFINYLMETHYL AND 7-SULFONYLMETHYL INDOLES AND USE THEREOF | HTR7, STS, INMT | MGAM 735/4885GAA 2822/4885SI 98/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.